non peptide WB4-24 inhibits inflammatory nociception - nomenclature-of-peptides Design of non-peptide agonists and antagonists at neuropeptide receptors The Expanding World of Non-Peptide Therapeutics: A Deep Dive

nonribosomal-peptide The realm of therapeutic development is increasingly exploring non-peptide molecules as alternatives to traditional peptide-based drugs. This shift is driven by the potential for improved stability, oral bioavailability, and simplified manufacturing processes. While peptides play crucial roles in biological systems, their susceptibility to degradation in the body often limits their therapeutic applicationsThe SignalP 6.0 server predicts the presence of signalpeptidesand the location of their cleavage sites in proteins from Archaea, Gram-positive Bacteria, Gram .... Consequently, researchers are investing significant effort into designing and discovering non-peptide agonists and antagonists that can effectively modulate biological targets previously addressed by peptides.Non-Peptide Gonadotropin-Releasing Hormone Receptor ...

A prominent area of focus for non-peptide drug development lies in targeting receptors like the glucagon-like peptide-1 receptor (GLP-1R).作者：MA Nauck·2023·被引用次数：12—Once-daily oral small molecule GLP-1R agonist PF-07081532reduces glucose and body weight within 4-6 weeksin adults with type 2 diabetes and ... GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity, primarily administered via injection due to the inherent limitations of peptides. However, the advent of small-molecule agonists of the glucagon-like peptide-1 receptor promises a new era of oral therapies. For instance, non-peptide, once-per-day oral orforglipron is emerging as a potential competitor to existing injectable GLP-1 receptor agonists. Studies have indicated that such non-peptide GLP-1 analogue, Orfoglipton, can induce weight loss and, as demonstrated in a phase II study targeting patients with type 2 diabetes, showed a significant reduction in glycated hemoglobin (HbA1c) and reduces glucose and body weight within 4-6 weeks. This development is particularly significant for patient convenience and adherence.

The scientific community is making considerable progress in discovering non-peptide GLP-1 allosteric modulators and agonists作者：MS Alturki·2025·被引用次数：3—The development of orally bioavailablenon-peptidomimetic glucagon-like peptide-1 receptor agonists(GLP-1RAs) offers a promising therapeutic avenue for the .... These non-peptidomimetic glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer a promising therapeutic avenue, potentially overcoming some of the challenges associated with peptide-based treatments. Research efforts include virtually screening natural product databases to find these modulators, aiming to leverage existing biological scaffolds. Furthermore, the development of non-peptide agonists and antagonists at neuropeptide receptors is also a significant area of investigation, building upon the understanding gained from studying the natural peptide ligands. The transition From Peptide to Non-Peptide is a complex but rewarding endeavor, often involving the elucidation of bioactive conformations and the design of molecules that mimic the essential structural features of peptides.

Beyond GLP-1R, the exploration of non-peptide agents extends to other critical biological pathways作者：F Malik·2022·被引用次数：43—Considerable progress has been made in discoveringnon-peptide agonistsand positive allosteric modulators (PAMs) of GLP-1 receptors with demonstrated efficacy.. For example, Non-peptide antagonists of GnRH-R (Gonadotropin-Releasing Hormone receptor) represent an important new class of potential therapeutics for various indications. Similarly, Non-Peptide Glycoprotein IIb/IIIa Inhibitors have been developed, with potent and selective non-peptide fibrinogen receptor antagonists showing promise作者：NA ElSayed·2025·被引用次数：610—A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptidestimulation test in the context of classification..

The concept of non-peptide molecules interacting with biological systems is not entirely new. Historically, research in synthesizing peptide analogs with improved stability has paved the way for understanding how to create more robust therapeutic agentsThe non-peptide GLP-1 receptor agonist WB4-24 blocks .... This includes exploring molecules that might not strictly be peptides themselves but interact with peptide receptors.作者：HS Moon·2011·被引用次数：7—In this report, the authors provide a review on the development ofnon-peptide GLP-1 receptor agonistsand introduce a novel agonist DA-15864. For instance, non-peptide ligands for peptide receptors have been a subject of study for decades, with advancements in medicinal chemistry enabling the design of molecules with tailored propertiesSignalP 6.0 - DTU Health Tech - Bioinformatic Services.

The field also encompasses a broader understanding of molecular interactions. While not directly related to therapeutic peptides, the study of non-peptide antigens recognized by T cells, such as those derived from mycobacteria, highlights the diverse ways non-peptide entities can elicit biological responses. Similarly, the classification of nonribosomal peptide as a class of peptide secondary metabolites produced by microorganisms demonstrates the natural occurrence of complex molecules that are structurally distinct from ribosomal peptides.

The ongoing research into non-peptide therapeutics signifies a crucial evolution in drug discovery. The ability to design orally bioavailable and stable non-peptide GLP-1 receptor agonists and similar molecules for other targets holds immense potential for improving patient outcomes and expanding treatment options for a wide range of diseases. The exploration of non-peptide agonists is not just about replacing peptides but about creating entirely new therapeutic modalities with distinct advantages. The journey from identifying a non-peptide lead compound to a clinically approved drug is rigorous, involving extensive preclinical and clinical trials to ensure safety and efficacy, such as the reported efficacy of non-peptide GLP-1 analogue, Orfoglipton, to induce weight loss. The ultimate goal is to develop therapies that are more accessible, effective, and convenient for patients worldwide.From Peptide to Non-Peptide. 1. The Elucidation of a Bioactive ...